GlassScriptPhysician profile
Emily Harkey
NPI 1841831708
$6,341.32
in general payments reported to CMS, 2019-2025
26 companies · $2,018 in 2025
The $2,018 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189 · 2022: $1,407 · 2023: $1,204 · 2024: $1,523 · 2025: $2,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,712 · Education: $33.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,712.22 |
| Education | $33.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,317.16 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,033.84 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $879.42 | 2021-2025 | |
| Janssen Biotech, INC. | $575.91 | 2022-2025 | Stelara, Tremfya |
| Celgene Corporation | $252.42 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.61 | 2022-2025 | Xifaxan |
| Qol Medical, LLC | $178.65 | 2022-2025 | Sucraid, Sucraid |
| Sandoz INC. | $142.05 | 2024-2025 | Hyrimoz |
| Celltrion USA INC. | $76.21 | 2025 | Vegzelma |
| Organon LLC | $69.82 | 2024-2025 | Renflexis, Hadlima |
| Amgen INC. | $69.28 | 2023-2025 | Avsola, Amjevita, Uplizna |
| Ironwood Pharmaceuticals, INC | $65.52 | 2022-2023 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.75 | 2023-2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $63.43 | 2022 | |
| Lilly USA, LLC | $59.71 | 2025 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $42.33 | 2023 | |
| Ardelyx, INC. | $40.62 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $38.26 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $36.26 | 2022-2023 | Rebyota |
| Urgo Medical North America, LLC | $30.02 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Gilead Sciences, INC. | $29.92 | 2022 | |
| Daiichi Sankyo INC. | $25.64 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.57 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $17.17 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $15.67 | 2022 | |
| Exact Sciences Corporation | $15.08 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Harkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.